Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 16/20 | 1.00 |
| ▸ | ESR1 | P03372 | 14/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 12/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.73 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.73 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.73 |
| ▸ | ESRRG | P62508 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | HTR6 | P50406 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28404807 | 1.00 | CYP19A1 (1.00) | CYP19A1ESR1ESR2CYP3A4CYP1A2 | |
| SCHEMBL24302096 | 1.00 | CYP19A1 (1.00) | CYP19A1ESR1ESR2CYP3A4CYP1A2 | |
| SCHEMBL906293 | 0.95 | ESR1 (0.90) | CYP19A1ESR1ESR2CYP3A4CYP1A2 | |
| SCHEMBL9098766 | 0.95 | ESR1 (0.90) | CYP19A1ESR1ESR2CYP3A4CYP1A2 | |
| SCHEMBL9098770 | 0.95 | ESR1 (0.90) | CYP19A1ESR1ESR2CYP3A4CYP1A2 | |
| SCHEMBL21478102 | 0.90 | ESR1 (0.81) | CYP19A1ESR1ESR2CYP3A4CYP1A2 | |
| SCHEMBL5738276 | 0.88 | ESR1 (0.79) | CYP19A1ESR1ESR2ESRRGLMNA | |
| SCHEMBL8362672 | 0.88 | ESR1 (0.79) | CYP19A1ESR1ESR2ESRRGLMNA | |
| SCHEMBL8362668 | 0.88 | ESR1 (0.79) | CYP19A1ESR1ESR2ESRRGLMNA | |
| SCHEMBL5738281 | 0.88 | ESR1 (0.79) | CYP19A1ESR1ESR2ESRRGLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4678638-A1 | NEW E3 UBIQUITIN LIGASE LIGAND, PROTEIN DEGRADATION AGENT AND USE THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2026-01-14 | — | — | EP | disclosed |
| EP-4446324-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2024-10-16 | — | — | EP | disclosed |
| WO-2024188209-A1 | NEW E3 UBIQUITIN LIGASE LIGAND, PROTEIN DEGRADATION AGENT AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2024-09-19 | — | — | WO | disclosed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |
| CN-116239566-A | E3 ubiquitin ligase ligand compound, protein degradation agent developed based on ligand compound and application thereof | 标新生物医药科技(上海)有限公司 | 2023-06-09 | — | — | CN | disclosed |
| US-20220117982-A1 | TARGET PROTEIN DEGRADATION COMPOUNDS, THEIR ANTI-TUMOR USE, THEIR INTERMEDIATES AND USE OF INTERMEDIATES | SHANGHAITECH UNIVERSITY (CN) | 2022-04-21 | — | — | US | disclosed |
| US-20220016102-A1 | ER PROTEIN REGULATORS AND USE THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2022-01-20 | — | — | US | disclosed |
| EP-3778590-A1 | PROTEIN DEGRADATION TARGETING COMPOUND, ANTI-TUMOR APPLICATION, INTERMEDIATE THEREOF AND USE OF INTERMEDIATE | ShanghaiTech University (CN) | 2021-02-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220016102-A1 | ER PROTEIN REGULATORS AND USE THEREOF | ESR2, ESRRG, ESRRA | CYP19A1 420/4885ESR1 5/4885ESR2 1/4885 |
| US-20220117982-A1 | TARGET PROTEIN DEGRADATION COMPOUNDS, THEIR ANTI-TUMOR USE, THEIR INTERMEDIATES AND USE OF INTERMEDIATES | UFM1, SUMO1, SUMO2 | CYP19A1 4145/4885ESR1 2864/4885ESR2 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.